Back to discover
Drug

Fucose

In clinical development
Emerging researchEarly-to-mid development

Also known as L-FUCOSE.

RxNorm2466731ChEMBLCHEMBL6067643UNII28RYY2IV3F
1
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Fucose
Aliases & brands
L-FUCOSE
RxNorm CUI
2466731
ChEMBL ID
CHEMBL6067643
UNII
28RYY2IV3F

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
LATEST COMPLETION 2018
1
Active studies
1
Recruiting
1
Completed
PHASE DISTRIBUTIONn = 2
Phase 1 / 21Phase 21

Recent completions

Trials that read out recently, adding to the completed evidence base.

Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II

CompletedPH I/IIOrpha Labsn=42018

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • Science (New York, N.Y.)1
Leading researchers
  • Bentlage AEH1
  • Brinkhaus M1
  • Brouwer PJM1
  • Chen HJ1
  • de Bruin S1
  • de Graaf EL1
  • de Taeye SW1
  • de Winther M1
Leading institutions
free-text, unnormalised
  • Amsterdam Infection and Immunity Institute1
  • Amsterdam Rheumatology and Immunology Center1
  • Center for Proteomics and Metabolomics1
  • Department of Rheumatology and Clinical Immunology1
  • Landsteiner Laboratory1
  • University of Amsterdam1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials